Pathogen/Target-Based Vaccine Design


Pathogen/Target-Based Vaccine Design

Creative Biolabs can offer advanced Vaccine Design for your specific requirements that cover Pathogen-Based Vaccine and Target-Based Vaccine. The pathway of a vaccine faces a high risk of attrition at many stages in the process from discovery through early development. Creative Biolabs’ strong expertise in vaccine design allows us to help clients tackle the challenges and accelerate the design and development of effective vaccines.

Vaccine Revolution

Vaccines have long been used to fight against infectious diseases and most currently available vaccines were empirically designed. However, immune evasion by pathogens often lead to difficulty in vaccine development. Revolutionary changes happened in the approach to vaccine design and development in the last decade. There is no longer a need to rely on the strenuous classical methods such as attenuation or killing the pathogen.

Vaccine Design

Scientists highly value the development of novel vaccines to induce protective immunity against selected pathogens. Rationally designed vaccines consist of antigens, delivery systems, and sometimes adjuvants which cause predictable immune responses against specific epitopes to protect against a pathogen.

Further data from empirically designed trials are required to identify biomarkers or patterns which can provide reliable guide prediction on efficacy and safety of vaccine at reasonable success rates.

Pathogen-Based Vaccine

Pathogen-Based Vaccine

Bacterial Vaccines contain attenuated or killed bacteria that activate the immune system. For Bacterial Vaccines, a pathogen strain is cultured and inactivated to produce a “whole-cell” vaccine (e.g., Bordetella pertussiss), an attenuated bacterium is used (BCG), or pathogen bacterial strains is cultured to produce inactivated and purified toxins or virulence factors (Clostridium tetani, Corynebacterium diphtheriae, B. pertussis).

Viral Vaccines contain either attenuated (alive but cannot cause disease) viruses or inactivated viruses. Attenuated or live vaccines include the live form of the virus. These viruses are not pathogenic but can induce an immune response. Inactivated or killed viral vaccines include viruses that have lost their ability to replicate. To cause immune reaction, it contains more antigen than live vaccines. For Viral Vaccines, adherent primary cells were usually cultured (chicken, rat cells for MMR, monkey cells for polio, eggs for influenza) in plastic roller bottles or glass (Roux) bottles, on membrane plates, and in bioreactor when microcarriers made it possible.

Target-Based Vaccine

It was not until recent years that the concept of cancer immunoediting became widely accepted. Scientists found that tumor progression was controlled by the immune system and modulate the immune response in turn. The immune system may offer a solution for two major problems in cancer treatment: off-target effects and tumor recurrence.

A therapeutic Cancer Vaccine can stimulate specific immunity against tumor issues while sparing normal ones, which lead to not only tumor lysis but also a long lasting, systemic immunological memory which protects against tumor recur and metastasis.

The generation of an efficacious antitumor immune response requires several important steps: (1) the existence of immunogenic tumor antigens; (2) the recruitment and maturation of antigen-presenting cells (APC)—mainly dendritic cells (DCs); (3) the uptake and processing of tumor antigens by mature DCs; and (4) the presence of costimulatory signals and stimulatory cytokines and the absence of inhibitory signals that together favor the induction of T helper-1 (Th1) cells, CD8+T cytotoxic lymphocytes (CTLs), and high-titer, high-affinity antibodies [1].

The goal of therapeutic cancer vaccine is to induce long-lasting antitumor immunity that can protect system against metastatic disease or tumor recurrence. Immunotherapy using therapeutic cancer vaccines may enhance the efficacy of existing regimens in late-stage disease while adding minimal toxicity and has the potential to address several unmet medical needs.

Pathogen/Target-Based Vaccine Design


  • Help develop vaccines with the appropriate immune response
  • Provide immunogenicity prediction for vaccine candidates
  • Identify epitopes and design the vaccines in-silico
  • Expert scientists from Creative Biolabs Vaccine Services team will help to analyze the data and to provide advice throughout the process

Creative Biolabs provides our customers a series of specialized Vaccine Design services. In terms of our abundant experience, Creative Biolabs is proud to help clients reduce the cost of failure and enhance the chance of clinical success.


  1. Wong KK; Li WA; et al. Vaccine process technology. Adv Immunol. 2016, 130: 191-249.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.